| |
|
From Principle to Practice: A Case Series Workshop in Clinical Mycology
|
Release Date: Friday, August 14, 2009
Credit Expiration Date: Saturday, August 14, 2011
|
|
Credit Hours
Physician CME: 1.0
Pharmacist CPE: 1.0 (0.10 CEUs)
Nurses CNE: 1.0
|
|
|
Activity Type
Application-based
|
|
Activity Overview
This CME/CE activity is based on a CME/CE symposium held during the 2009 BMT Tandem Meetings on
February 14 in Tampa, Florida. It consists of audio, charts, graphs, tables, and text and has 4 learning modules.
- Aspergillosis: Early Diagnosis Equals Better Outcomes
- Antifungal Prophylaxis: Identifying Patients at Greatest Risk
- Drug Safety and Monitoring
- Salvage Therapy: When All Else Fails
The first three learning modules begin with a case introduction by Dr. Patterson or Dr. Perfect. You will
then be asked clinically important questions. Please take a moment to think about what you would do and
select your answer. After you make a selection, you will have the opportunity to review Dr. Patterson’s
or Dr. Perfect’s explanation from the symposium regarding important considerations that should guide the
decision-making for that case. In the last learning module on salvage therapy, Dr. Perfect presents important
clinical considerations through a series of case vignettes.
|
|
Educational Overview
Dramatic advancements in the diagnosis and treatment of invasive fungal infections (IFIs) have decreased the risk
for morbidity and mortality in hematopoietic stem cell transplant (HSCT) recipients. Through the use of new
diagnostic techniques, clinicians are able to detect and identify these infections early on, providing targeted
therapy at a time when treatment is most effective. At the same time, newly available antifungal agents provide
additional treatment options, creating greater opportunity for clinicians to select therapy that is both effective
and safe. Also, recent clinical studies have provided further insight on the significance of antifungal prophylaxis
and how to identify those patients who would benefit most from this strategy.
When used appropriately, these advancements can help assure better patient outcomes. Keeping abreast of the latest
research is more important than ever, as treatment algorithms are rapidly evolving. This program is designed to
further clinicians’ knowledge of novel diagnostic techniques and therapeutic strategies. A series of cases will
illustrate how the latest research can be applied to everyday clinical practice for the benefit of transplant
patients. Four issues relevant to the management of HSCT recipients will be the focus of discussion: antifungal
prophylaxis, early diagnosis, Aspergillus infections, and salvage therapy.
|
|
Target Audience
The target audience for this online activity consists of those healthcare professionals who are involved
in the daily care of patients undergoing bone marrow and stem cell transplantation. This includes
oncologists, hematologists, pediatricians, immunologists, clinical pharmacists, and transplant nurses.
|
|
Learning Objectives
Upon completion of this activity, learners should be able to:
- Evaluate strategies for the prevention and treatment of invasive fungal infections in HSCT patients
- Discuss the importance of safe, appropriate use of antifungal agents in achieving optimal clinical outcomes
|
|
Faculty Contributors
Thomas F. Patterson, MD, FACP, FIDSA
Professor of Medicine
Chief, Division of Infectious Diseases
Director, San Antonio Center for Medical Mycology
The University of Texas Health Science Center at San Antonio
San Antonio, TX
John R. Perfect, MD
Professor of Medicine
Chief, Division of Infectious Diseases (Interim)
Duke University Medical Center
Durham, NC
|
|
Accreditation
Physicians
Accreditation Statement: This activity has been planned and implemented in accordance with the Essential Areas and
Policies of the Accreditation Council for Continuing Medical Education (ACCME) through joint sponsorship
of The Medical College of Wisconsin and Syntaxx Communications, Inc. The Medical College of Wisconsin is
accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation: The Medical College of Wisconsin designates this educational activity for a maximum
of 1 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their
participation in the activity.
Pharmacists
 Accreditation
Statement: Syntaxx Communications, Inc. is accredited by the Accreditation Council
for Pharmacy Education as a provider of continuing pharmacy education.
Credit Designation: Syntaxx Communications, Inc. has assigned 1.0 contact hour (0.10 CEUs) of continuing pharmacy education
credit to this activity.
ACPE Universal Activity Number: 299-999-09-901-H04-P
Estimated time to Complete Activity: 1.0 hours
Nurses
The activity is approved for 1.0 contact hour of credit which includes 42 minutes of pharmacology content of
nursing CE. This continuing nursing education activity was approved by Oncology Nursing Society, an
accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation.
Approval number: 4324
|
|
Method of Participation and Instruction for Credit
There is no fee to participate in this Internet activity. To receive a CME Certificate or Statement of
Credit, participants must review the CME/CE information including learning objectives and disclosure
statements, review the entire activity, and complete a Post Test, Evaluation, and Credit Application Form.
Physician learners should fax or mail the completed Post Test, Evaluation, and Credit Application Form
to (414) 456-6623 or Office of Continuing & Professional Education, Medical College of
Wisconsin (RPC 125), 8701 Watertown Plank Road, Milwaukee, WI 53226.
A CME Certificate will be mailed 4–6 weeks upon receipt of materials.
Pharmacist learners and nurse learners should fax or mail the completed Post Test, Evaluation, and Credit
Application Form to (678) 584-9661 or Department of Continuing Education, Syntaxx Communications, 305 West
Country Drive, Duluth, GA 30097-5906.
A Statement of Credit will be mailed 4–6 weeks upon receipt of materials.
|
|
Disclosure of Conflict of Interest
Medical College of Wisconsin and Syntaxx Communications, Inc. require faculty, planners, and others who
are in a position to control the content of continuing education activities to disclose to the audience
any real or apparent conflict of interest related to the activity. All identified conflicts of interest
are reviewed to ensure fair balance, objectivity, and scientific rigor in all activities. The faculty is
further required to disclose discussion of off-label uses in their presentations.
|
|
Disclosures
Faculty
Thomas F. Patterson, MD, FACP, FIDSA
- Research/grant support: Basilea and Schering-Plough
- Speaker/consultant and received honoraria: Basilea, Merck, and Pfizer
John R. Perfect, MD
- Research/grant support: Astellas, Basilea, Enzon, Merck, Pfizer, and Schering-Plough
- Advisor/educator and received honoraria: Astellas, Basilea, Enzon, Merck, Pfizer, and Schering-Plough
Planning Committee Members
Employees of Medical College of Wisconsin and Syntaxx Communications have no relevant financial relationships to disclose.
Disclosure of Off-label Use
During this activity, off-label use of the following antifungal agents are discussed: amphotericin B lipid
complex (for prophylaxis), liposomal amphotericin B (at a dose of 10 mg/kg/day), posaconazole (for invasive
aspergillosis), itraconazole (for prophylaxis), voriconazole (for prophylaxis), aerosolized formulations of
amphotericin B (for prophylaxis), and combination antifungal therapy (for treatment of invasive fungal infections).
|
|
Joint Sponsorship
This activity is jointly sponsored by The Medical College of Wisconsin and Syntaxx Communications, Inc.
|
|
Commercial Support
This activity is supported by an educational grant from Schering-Plough Corporation.
|
|
Fee
There is no fee to participate in this educational activity.
|
|
Hardware/Software Requirements
Web Browser
Internet Explorer or Mozilla
Note: Please disable any “pop-up blocker” features.
Software
Flash Player to view the presentations
Adobe Acrobat Reader version 4 or above to view PDF files (If you do not have Acrobat Reader, you can download it
for free from http://get.adobe.com/reader)
Connection Speed
Cable, DSL, or better of at least 300 kbps
Hardware
PC or Apple to view the presentations
Audio Speakers
System Check
Please e-mail any questions or concerns to info@vemcomeded.com.
|
|
Copyright Statement
Copyright © 2009 Vemco MedEd, LLC. All Rights Reserved.
Permission for accreditation use granted to Center for Independent Healthcare Education.
|
|
Disclaimer
The opinions expressed in this educational activity are those of the faculty and do not reflect the views of The
Medical College of Wisconsin and Syntaxx Communications. This educational activity may discuss off-label and/or
investigational uses and dosages for therapeutic products/procedures that have not been approved by the United States
Food and Drug Administration (FDA). The Medical College of Wisconsin and Syntaxx Communications do not recommend
the use of any product/procedure outside of the labeled indications. A qualified healthcare professional should be
consulted before using any therapeutic product/procedure discussed. Clinicians should verify all information and
data before treating patients or employing any therapies described in this continuing education activity. Please
refer to the prescribing information for each product/procedure for approved indication, contraindications, and warnings.
|
|
Privacy Policy
http://www.vemcomeded.com/privacy.asp
|
|
Contact Information
For questions regarding the accreditation of this activity, please contact:
- For physician learners: CME Registrar, Medical College of Wisconsin, (414) 456-4900
- For pharmacist and nurse learners: Ross Davidson, Syntaxx Communications, Inc., (678) 584-9503
or rdavidson@syntaxxcomm.com
|
Start Activity
|
By clicking on the icon to begin the educational activity, I acknowledge that I have read the entire CME/CE information.
|
|
|
|
|
|
|
|
|
|
|
|
